Adjuvant radiotherapy of the pelvis with or without reduced glutathione: a randomized trial in patients operated on for endometrial cancer.
A randomized pilot trial was performed to evaluate the feasibility of administration of glutathione (GSH, 1200 mg, i.v.) as a protector in preventing diarrhea in patients operated on for endometrial cancer and submitted to adjuvant radiotherapy of the pelvis. Diarrhea occurred in 52% of patients in the untreated control group and only in 28% of patients in the GSH-treated group. Our preliminary data indicate that GSH administered before radiotherapy reduced the occurrence of diarrhea from oxidative damage to the intestinal mucosa. A large-scale phase III study is required to obtain definitive conclusions on the protective potential of GSH.
De Maria
D
D
Radiotherapy Department, University of Modena, Italy.
Falchi
A M
AM
Venturino
P
P
D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D003967:Diarrhea / Q000209:etiology / Q000517:prevention & control*; D016889:Endometrial Neoplasms / Q000532:radiotherapy* / Q000601:surgery; D005240:Feasibility Studies; D005260:Female; D005978:Glutathione / Q000627:therapeutic use*; D006801:Humans; D007413:Intestinal Mucosa / Q000473:pathology / Q000528:radiation effects; D008875:Middle Aged; D010865:Pilot Projects; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D011878:Radiotherapy / Q000009:adverse effects
D011837:Radiation-Protective Agents; D005978:Glutathione